Elevation Oncology earnings were -$44.5M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest ELEV earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$10.4M, down 19% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ELEV reported annual earnings of -$44.5M, with -2.7% growth.
What were Elevation Oncology's earnings last quarter?
Elevation Oncology (NASDAQ: ELEV) reported Q4 2024 earnings per share (EPS) of -$0.18, up 63.64% year over year. Total ELEV earnings for the quarter were -$10.44 million. In the same quarter last year, Elevation Oncology's earnings per share (EPS) was -$0.11.
As of the last Elevation Oncology earnings report, Elevation Oncology is currently losing money. Elevation Oncology's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$44.49 million, a 2.67% decrease year over year.
What was ELEV's earnings growth in the past year?
As of Elevation Oncology's earnings date in Q2 2025, Elevation Oncology's earnings has grown year over year. ELEV earnings in the past year totalled -$44.49 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.